Surgery – Truss – Pad
Patent
1995-01-27
1997-05-27
Lateef, Marvin M.
Surgery
Truss
Pad
A61B 505
Patent
active
056322763
ABSTRACT:
A method and apparatus for screening patients for nervous system dysfunction including neurological capacity and dysfunction. A patient profile of actual functional activity of a brain of a patient is produced and compared with at least one marker. The marker is a profile of predetermined functional activity at a plurality of sets of predetermined coordinates of a given brain geometry.
REFERENCES:
patent: 4307726 (1981-12-01), Paulson et al.
patent: 5215095 (1993-06-01), Macvicar et al.
patent: 5265945 (1993-11-01), DeCarli et al.
patent: 5299119 (1994-03-01), Kraf et al.
patent: 5302583 (1994-04-01), Costa et al.
patent: 5438989 (1995-08-01), Hochman et al.
patent: 5445937 (1995-08-01), Haley
The Metabolic Topography of Normal Healthy Aging, Neurology 44 (Suppl 2), Apr. 1994, A164.
The Metabolic Topography of Normal Aging, Journal of Celebral Blood Flow and Metabolism vol. 15, Supp. 1, Jul. 1995, p. S593.
The Metabolic Topography of Normal Aging, Journal of Cebral Blood Flow and Metabolism vol. 16, No. 3, 1996, p. 385-398.
Alexander, G.E., Moeller, J.R., Application of Scaled Subprofile Model analysis to functional imaging of neurological disorders:A principal component approach to modeling regional patterns of brain function in disease, Human Brain Mapping 2 (1194) 79-94.
Variability in Regional Cerebral Metabolic Rate for Glucose (rCMRGlu) and its Consequences for the Study of Neurological Disease with FDG/PET, Mar. 1988, Neurology 38,(Supp 1), 367.
The metabolic anatomy of Parkinson's disease:complementary 18Ffluorodeoxyglucose and 18Ffluorodopa positron emission tomographic studies, Mov Discord, 1990, 5(3), p. 203-213.
The Metabolic Pathology of Parkinson's Disease: Complementary 18F-Fluorodopa and 18F-Fluorodeoxyglucose PET Studies, vol. 39(3), Suppl 1, Mar. 1989, p. 273.
The metabolic topography of parkinsonism, J Cereb Blood Flow Metab, (U.S.), Sep. 1994, 14(5), pp. 783-801.
Brain Metabolic Topography In Parkinsonism, vol. 43(4), Supp. 2, Apr. 1993, p. A270.
Brain Metabolic Topography In the Movement Disorders, vol. 13, Supp. 1, May 1993, p. S9.
The metabolic topography of idiopathic torsion dystonia, Brain (England), Dec. 1995, 118 (Pt 6), pp. 1473-1484.
Brain Metabolic Topography In Idiopathic Torsion Dystonia, vol. 43(4), Supp. 2, Apr. 1993, p. A408.
Early differntial diagnosis of Parkinson's disease with 18F-Fluorodeoxyglucose and positron emission tomography, Neurology (US), Nov. 1995, 45(11), pp. 1995-2004.
Detection of Early Parkinson's Disease With 18F-Fluorodeoxyglucose and Positron Emission Tomography, Neurology 44, Supp. 2. Apr. 1994, p. A352.
Detection of Early Parkinson's Disease With 18F-Fluorodeoxyglucose and Positron Emission Tomography, Journal of Nuclear Medicine, No. 31, Jun. 1994, p. 10p.
Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET J Nucl Med (US), Mar. 1995, 36(3). pp. 378-383.
FDG/PET Predicts Clinical Disability in Parkinson's Disease, vol. 44(4), Supplement to Neurology, May, 1994, p. A280.
Visualizing the evolution of abnormal metabolic networks in the brain using PET,Comput Med Imaging Graph (US), May-Jun. 1995, 19(3), p. 295-306.
Visualizing Patterns of Neurological Disease Progression with PET, Physics of Medical Imaging Feb. 1994, pp. 2168-2227.
Eidelberg David
Moeller James R.
Casler Brian L.
Lateef Marvin M.
LandOfFree
Markers for use in screening patients for nervous system dysfunc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers for use in screening patients for nervous system dysfunc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers for use in screening patients for nervous system dysfunc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2322364